2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLOS ONE 2022, 17: e0267780. PMID: 35657826, PMCID: PMC9165827, DOI: 10.1371/journal.pone.0267780.Peer-Reviewed Original ResearchConceptsClinical trialsHIV incidencePre-exposure prophylaxis clinical trialHispanic/LatinxRecruitment goalsGood participatory practice guidelinesOngoing phase 3 trialsHIV pre-exposure prophylaxisTransgender womenTransgender menPhase 3 trialPre-exposure prophylaxisCommunity-based clinicsFuture clinical trialsClinical trial numberEvidence-informed recommendationsLatinx MSMGender nonbinary individualsCisgender MSMNovel agentsPractice guidelinesStudy populationBlack MSMUS sitesTrialsSafety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. The Lancet Infectious Diseases 2022, 22: 636-648. PMID: 35090638, PMCID: PMC8789245, DOI: 10.1016/s1473-3099(21)00764-7.Peer-Reviewed Original ResearchConceptsHigh-dose groupLow-dose groupMedium-dose groupGeometric mean titresAdverse eventsRecombinant protein vaccineCOVID-19 vaccineSecond vaccinationSARS-CoV-2Day 36Antigen doseAdverse reactionsProtein vaccineMedical conditionsVaccine-related serious adverse eventsHigh-risk medical conditionsInteractive response technology systemAntibody geometric mean titresPre-existing medical conditionsCandidate vaccine formulationsCoV2 preS dTMPrevious phase 1Primary immunogenicity objectivePseudovirus neutralization assayUnsolicited adverse events
2021
High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities
Ogbuagu O, Wachekwa I, Yasin F, Nuta C, Donato S, Toomey J, Adeiza M, Barakat LA. High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities. Annals Of Global Health 2021, 87: 117. PMID: 34900617, PMCID: PMC8622250, DOI: 10.5334/aogh.3243.Peer-Reviewed Original ResearchConceptsHIV testing dataNon-pregnant individualsHIV detection rateTertiary facilityPrevention interventionsJohn F. Kennedy Medical CenterHospital-based retrospective analysisSignificant public health challengeStudy periodAnnual diagnosis ratePre-exposure prophylaxisPositive HIV testLarge tertiary hospitalCase detection ratePublic health challengeYears of ageNational prevalence estimatesDetection rateHIV/AIDSAntenatal clinicHIV testHIV testingTertiary hospitalPregnant womenUNAIDS 95
2018
Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda
Kambutse I, Igiraneza G, Ogbuagu O. Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PLOS ONE 2018, 13: e0207650. PMID: 30475841, PMCID: PMC6261021, DOI: 10.1371/journal.pone.0207650.Peer-Reviewed Original ResearchConceptsKigali University Teaching HospitalPre-exposure prophylaxisNew HIV infectionsHealth care workersHIV infectionHIV transmissionHealth facilitiesCare workersUniversity Teaching HospitalService delivery barriersMultiple community sitesSafer sex practicesPrEP implementationHIV testingHealthcare workersSmoking cigarettesTeaching hospitalMosquito bitesPrevention servicesHIVNew infectionsHealthcare providersHealthcare professionalsPrEPSex practices